Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab and Gemcitabine in Recurrent Ovarian Cancer
NCT01296035Phase 2Terminated
- Sponsor
- Women & Infants Hospital
- Start
- Feb 2011
- Primary completion
- Oct 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Women & Infants Hospital. Primary endpoint: Overall Response Rate. Started Feb 2011; status: terminated.
02
Drugs
panitumumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01296035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01296035.